07:29 AM EDT, 06/25/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Tuesday a phase 3 trial of its cancer drug Imfinzi combined with chemotherapy showed "statistically significant and clinically meaningful" improvement in the primary endpoint of event-free survival in patients with muscle-invasive bladder cancer.

High-level data from the trial also showed similar results for the key secondary endpoint of overall survival compared with neoadjuvant chemotherapy, the company said.

Participants in the study received Imfinzi with chemotherapy before bladder removal surgery and continued with Imfinzi as adjuvant monotherapy, AstraZeneca ( AZN ) said.

The company also said Imfinzi was "generally well-tolerated" with no new safety concerns in either the neoadjuvant or adjuvant setting.

Price: 79.61, Change: +0.24, Percent Change: +0.30